Results 91 to 100 of about 755,616 (163)
Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2 [PDF]
, 2002 Receptor tyrosine kinases (RTKs) play distinct roles in multiple biological systems. Many RTKs transmit similar signals, raising questions about how specificity is achieved.Zhang, S., Wen, G., Minichiello, L., Zhang, Si Qing, Wen, Gengyun, Araki, T., Klein, R., Tsiaras, B., Neel, Benjamin G, Neel, B., Araki, Toshiyuki, Klein, Ruediger, Minichiello, Liliana, Tsiaras, William G +13 morecore +1 more sourceDiscovery of GDC-0853:
A Potent, Selective, and Noncovalent
Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
, 2018 Bruton’s
tyrosine kinase (Btk) is a nonreceptor cytoplasmic
tyrosine kinase involved in B-cell and myeloid cell activation, downstream
of B-cell and Fcγ receptors, respectively.Liming Dong (734480), Rebecca Erickson (4885756), Harvey Wong (1638931), Melis Coraggio (4885762), Adam R. Johnson (1638925), Arna Katewa (2399662), Dinah L. Misner (4885753), Nico Ghilardi (201347), James J. Crawford (1464994), Leah Schutt (4885750), Pawan Bir Kohli (1947676), Karin Reif (2069485), Regina Choy (3105528), BinQing Wei (2128288), Georgette Castanedo (2044339), Suzanne Tay (1551283), Lisa D. Belmont (640344), Wendy Lee (333665), Joseph W. Lubach (1415983), Lichuan Liu (438088), Daniel F. Ortwine (1600621), Charles Eigenbrot (1346406), Wendy B. Young (2201095), Brent S. McKenzie (4885759), Jonathan Hau (4885747) +24 morecore +2 more sourcesReactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies
Transplant Infectious Disease, EarlyView.In adults with hematologic malignancies, RSV vaccination was safe and induced antibody and T‐cell responses. However, antibody levels were lower and declined more rapidly than in healthy controls. While early immune responses were evident, reduced magnitude and durability of protection suggest the need for optimized vaccination strategies in this high ...Alisse Hannaford, Zoe Swank, Simon D. van Haren, Natalie Izaguirre, Caitlin Syphurs, Zhou Lan, Bridget Yates, Urwah Kanwal, Grace Valentine, Ella Woehl, David Regan, Hannah Levine, Alexandra Tong, Maria Shehata, Fathia Oladipupo, Colleen Sedney, Kevin Ryff, Sanya Thomas, Joann Diray‐Arce, Xiaofang Li, Kimberly A. Dufresne, Lindsey A. Parisi, Aidan Eustace, Louise Hansen, David R. Walt, Ofer Levy, Amar Kelkar, Robert J. Soiffer, Vincent T. Ho, Lindsey R. Baden, Nicolas C. Issa, Ann E. Woolley, Amy C. Sherman +32 morewiley +1 more sourceBruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
ImmunoTargets and Therapy, 2021 Laura C Arneson,1,* Kristen J Carroll,1,* Eric M Ruderman2 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School ...Arneson LC, Carroll KJ, Ruderman EMdoaj Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Background
Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...John M. Burke, Ira Zackon, Yunfei Wang, Kathleen M. Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Siyang Leng, Inkyu Kim, Diana Chirovsky, Enrico de Nigris +10 morewiley +1 more sourceP1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING
HemaSphere, 2023 Subbaiah Chary Nimmagadda, Paulina Marie Budde, Kaiyan Sun, Todd Covey, Cecile Krejsa, Wayne P. Rothbaum, Nikolas von Bubnoff, Cyrus Khandanpour +7 moredoaj +1 more sourceAtrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Introduction
Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods
We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.Andrea Visentin, Enrica Antonia Martino, Alessandro Cellini, Francesco Angotzi, Annalisa Pitino, Andrea Duminuco, Ernesto Vigna, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Anna Maria Frustaci, Marcello Riva, Sara Pepe, Adalberto Ibatici, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Francesco Malaspina, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Fraticelli, Candida Vitale, Azzurra Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozella, Luigi Malandruccolo, Marzia Varettoni, Lucia Morello, Giuseppe Pietrantuono, Esmeralda Conte, Martina Cantelli, Roberta Murru, Daniele Caracciolo, Enrico Derenzini, Valentina Di Martina, Roberto Marasca, Maria Ilaria Del Principe, Amalia Figuera, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Nicola Amodio, Alessandro Allegra, Vittorio Del Fabro, Paolo Fiumara, Luca Scalise, Fabio Stagno, Giorgio Tona, Pellegrino Musto, Laura Caruso, Arcangelo Liso, Alessandra Tedeschi, Gianluca Gaidano, Francesca Romana Mauro, Giovanni Tripepi, Fortunato Morabito, Giuseppe Alberto Palumbo, Francesco Di Raimondo, Valter Gattei, Livio Trentin, Massimo Gentile +92 morewiley +1 more sourceDeep evolutionary conservation of an intramolecular protein kinase activation mechanism [PDF]
, 2012 DYRK-family kinases employ an intramolecular mechanism to autophosphorylate a critical tyrosine residue in the activation loop. Once phosphorylated, DYRKs lose tyrosine kinase activity and function as serine/threonine kinases.Cleghon Vaughn, Aman Singh (191216), Cleghon, V., Nathan Luebbering (191210), Sibbet Gary, Jingfen Han, Luebbering Nathan, Nathan Luebbering, Michael A J Ferguson, Singh, A., Aman Singh, Ferguson, M.A.J., Ferguson Michael A. J., Hong, W., Diego Miranda-Saavedra (36622), Michael A. J. Ferguson (166662), Jingfen Han, Han, J., Gary Sibbet (191221), Vaughn Cleghon (191224), Miranda-Saavedra Diego, Sibbet, G., Ferguson, M.A.J.; id_orcid, Han Jingfen, Miranda-Saavedra, D., Gary Sibbet, Luebbering, N., Diego Miranda-Saavedra, Michael A. J. Ferguson, Vaughn Cleghon, Singh Aman, Jingfen Han (191204) +31 morecore +1 more sourceA Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Introduction
BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.Steven M. Bair, John C. Byrd, Jonathan Gutman, Mitchell Phelps, Amy J. Johnson, Bita Fakhri, Kerry A. Rogers, Jennifer A. Woyach, Michael R. Grever, Manali Kamdar, Steven E. Coutre, Daniel A. Pollyea +11 morewiley +1 more source